Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibikase TherapeuticsIKT 35 Earnings per Share (Diluted) is $-0.43 as of Jun. 2026. GuruFocus rates IKT with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,158 Biotechnology companies, Inhibikase Therapeutics ranks better than 85.23% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was 51.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 28.50% per year.
During the past 8 years, Inhibikase Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 51.00% per year. The lowest was -55.70% per year. And the median was -7.70% per year.
Inhibikase Therapeutics (NAS:IKT) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Inhibikase Therapeutics Earnings per Share (Diluted) Related Terms
Inhibikase Therapeutics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Inhibikase Therapeutics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics Earnings per Share (Diluted) Chart
IKT vs ABEO, STRO, AGEN: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Inhibikase Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's PE Ratio falls into.
Inhibikase Therapeutics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Inhibikase Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.43 mean?
Inhibikase Therapeutics (IKT) has a Earnings per Share (Diluted) of $-0.43 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Inhibikase Therapeutics and its competitors. According to the industry distribution chart, Inhibikase Therapeutics ranks #171 out of 1158 companies in the Biotechnology industry, placing it in the top 14.8%.
Is Inhibikase Therapeutics' Earnings per Share (Diluted) too high?
Inhibikase Therapeutics' current Earnings per Share (Diluted) is $-0.43. Based on the distribution chart, Inhibikase Therapeutics ranks #171 out of 1158 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Earnings per Share (Diluted) compare to ABEO and STRO?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #171 out of 1158 companies for Earnings per Share (Diluted). This places Inhibikase Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 15.95, based on 1,158 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Inhibikase Therapeutics and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current Earnings per Share (Diluted) is $-0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Earnings per Share (Diluted) of $-0.43. The current Earnings per Share (Diluted) is $-0.43. Inhibikase Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Earnings per Share (Diluted) is $-0.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
35GF Score
Get the complete analysis for IKT
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
